TKI Dose Escalation After mRCC Progression Beneficial

, Homepage Feature, Treatment OptionsTKI Dose Escalation After mRCC Progression Beneficial

Dosevitaminspillsts481636226_1016727 escalation of tyrosine kinase inhibitors (TKIs) after disease progression in patients with metastatic renal cell carcinoma (mRCC) can lead to a decrease in tumour burden and extend duration of therapy, according to a study. Read more

2016-10-04T17:16:49+00:00October 4th, 2016|Drug treatments, Homepage Feature, Treatment Options|
This website uses cookies and third party services to provide a better service. Please confirm you are okay with this. I agree